一名转移性肝细胞癌患者在瑞戈非尼联合治疗及手术后实现长期缓解。
Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery.
作者信息
Goio Elisabetta, Ielasi Luca, Benevento Francesca, Renzulli Matteo, Tovoli Francesco
机构信息
Department of Medical & Surgical Sciences, Unit of Internal Medicine, University of Bologna, Bologna, 40138, Italy.
Unit of Radiology, S Orsola-Malpighi Bologna Authority Hospital, Bologna, 40138, Italy.
出版信息
Hepat Oncol. 2020 Jul 3;7(3):HEP24. doi: 10.2217/hep-2020-0014.
AIMS
The therapeutic scenario of systemic treatments for hepatocellular carcinoma (HCC) is rapidly changing. There is much interest in the possibility of combining new therapies with surgery, but clinical data is lacking. We aimed to provide an example of such integration.
PATIENTS & METHODS: We report a patient with metastatic HCC who received regorafenib in the setting of the RESORCE trial.
RESULTS
A brilliant response led to a tumor downstaging and a subsequent adrenal metastasectomy with radical intent.
CONCLUSIONS
New agents will change the therapeutic perspectives in advanced HCC and lead to a higher rate of objective responses, with possibilities of associating systemic therapy and surgery. Thus, the management of HCC will require more and more of an integrated, multidisciplinary and personalized approach.
目的
肝细胞癌（HCC）全身治疗的治疗方案正在迅速变化。人们对将新疗法与手术相结合的可能性很感兴趣，但缺乏临床数据。我们旨在提供这种整合的一个例子。
患者与方法
我们报告了一名转移性HCC患者，该患者在RESORCE试验中接受了瑞戈非尼治疗。
结果
显著的反应导致肿瘤降期，随后进行了根治性肾上腺转移灶切除术。
结论
新药物将改变晚期HCC的治疗前景，导致更高的客观缓解率，并有可能将全身治疗与手术相结合。因此，HCC的管理将越来越需要综合、多学科和个性化的方法。
Zotero 插件